Thursday, October 15, 2026

Government Finance & Fiscal Policy

3 articles

Tax Cut Bill Moves Social Security Insolvency to 2032, Triggers 27% Benefit Reduction

Tax Cut Bill Moves Social Security Insolvency to 2032, Triggers 27% Benefit Reduction

The One Big Beautiful Bill Act accelerates Social Security's insolvency timeline to 2032, six years earlier than previous projections, forcing automatic 27% benefit cuts for all recipients. The legislation's revenue reductions compound fiscal pressures as Fed Chair Jerome Powell's May 2026 term expiration creates uncertainty over monetary policy independence during the crisis.

ViaNews Editorial Team (Finance)•
One Big Beautiful Bill Act threatens $5.5 trillion debt increase, accelerates Social Security insolvency to 2032

One Big Beautiful Bill Act threatens $5.5 trillion debt increase, accelerates Social Security insolvency to 2032

The proposed legislation could add $5.5 trillion to national debt by 2034 while pushing Social Security insolvency forward three years to 2032, according to the Committee for a Responsible Federal Budget. The fiscal deterioration coincides with Federal Reserve Chair Jerome Powell's term expiration in May 2026, raising concerns about monetary policy independence as banks face mounting sovereign debt exposure.

ViaNews Editorial Team (Finance)•
US Debt Projected to Rise $5.5 Trillion by 2034 as Social Security Insolvency Looms in 2032

US Debt Projected to Rise $5.5 Trillion by 2034 as Social Security Insolvency Looms in 2032

The One Big Beautiful Bill Act will add $5.5 trillion to national debt by 2034, according to the Committee for a Responsible Federal Budget. Social Security's retirement trust fund faces bankruptcy between 2032-2035, threatening 24% benefit cuts. The fiscal crisis coincides with Fed Chair Jerome Powell's term expiring in May 2026.

ViaNews Editorial Team (Finance)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com